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Abstracts of the 12th ISIIH 2S15 
time of infection, naloxone or naltrexone were added 
in the absence or presence of zidovudine (AZT) or 
indinavir, at concentrations selected to give suboptimal 
(about 25%) viral suppression (measured by quantifying 
p24 antigen in culture supernatants) 
Results: While neither naloxone nor naltrexone alone 
displayed any anti-HIV-l activity, at concentrations bet- 
ween 1O-‘4-1O-s M, these opiate antagonists potentiated 
by 2-3 fold the antiviral activity of AZT and indinavir 
against both HIV-l AT and HIV-1~~162. The synergistic 
effect of naloxone/ naltrexone was dose-dependent with 
maximal stimulation in the picomolar to nanomolar 
range. Similar results with a K-OpiOid receptor (KOR) 
selective antagonist supported involvement of KOR in 
naloxone’s potentiation of antiretroviral drugs. 
Conclusions: Naloxone potently enhances the anti-HIV- 
1 activity of AZT and indinavir in CD4’ lymphocytes 
in vitro. Since naltrexone is a safe and relatively in- 
expensive drug that can be administered orally, clinical 
trials should be considered to see if this opiate antagonist 
also potentiates the activity of antiretrovirals in vivo. 
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Objective: Toxoplasmic encephalitis (TE), the leading 
cause of focal cerebral lesions in patients with AIDS, is 
presumed to result from recrudescence of latent 
Toxoplasma gondii infection. Since treatment of a TE 
episode requires life-long maintenance therapy, which 
may cause considerable toxicity, this remains a major 
therapeutic problem. Following up on our observations 
of a synergistic effect of atovaquone (ATO) and 
clindamycin (CLI) in acute murine toxoplasmosis, the 
effect of this drug combination was evaluated in a 
murine model of corticoid-drug induced recrudescence 
of chronic infection. 
Experimental design: Swiss-Webster mice with chronic 
toxoplasmosis established by intraoesophageal inocu- 
lation of 10 cysts of the Me49 strain of T gondii 3 months 
previously, were immunosuppressed with: a) dexa- 
methasone (DXM) at 2.5 mg/kg/day in drinking water 
(5 mg/L) alone or combined with cortisone-acetate (CA) 
at 50 mglkg by SC injection 3 times/ week during 3 weeks, 
and then treated with ATO+CLI at 5+25 and 50+50 
mg/kg/day for 4 weeks, and b) DXM alone during 2 
weeks, and treated with ATO+CLI at 25+50, 50+50, 
and 100+400 mg/kg/day for 3 weeks. Treatment effects 
were monitored by survival and brain cyst counts 
immediately after treatment (a), and both after treat- 
ment and 12 weeks later (b). 
Results: In chronically infected mice, corticoid admini- 
stration induced recrudescence of T gondii within 
weeks. The dramatically decreased survival rates and 
significantly increased brain cyst burdens compared 
to untreated mice, were both more expressed in mice 
suppressed with DXM+CA than with DXM alone. 
Treatment of immunosuppressed mice with AT0 and 
CL1 had a beneficial effect which was directly dependent 
on the drug dose, and indirectly on the level of immuno- 
suppression. Compared to 0% survival in untreated 
immunosuppressed controls, treatment with ATO+CLI 
at 50+50 mg/kg/day protected 30% DXM+CA pre- 
treated mice, while reducing the mean cyst burdens by 
4-fold. In mice pre-treated with DXM alone, the survival 
rate of 9% in untreated mice was elevated to 55-67% 
(PcO.05) in those treated depending on the dose 
regimen, and associated with markedly decreased cyst 
burdens (PcO.01). The latter effect was long-term since 
the cyst burdens in treated animals continued to 
decrease over the next 3 months, while significantly 
(PcO.01) rising in the control ones. 
Conclusions: The data presented suggest that the 
combination of AT0 and CL1 may be a novel option 
for the treatment of toxoplasmosis in the setting of 
immunosuppression, warranting its clinical evaluation. 
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Paracoccidioidomycosis is a deep-seated systemic 
infection of humans caused by the thermal dimorphic 
fungus Paracoccidiodes brasiliensis and a major problem 
in Central and South America. On the other hand, AIDS 
epidemic can influence the evolution of endemic in- 
fectious diseases. A case of paracoccidioidomycosis in 
a patient with AIDS is described, this is the first 
association of paracoccidioidomycosis with AIDS in 
Bolivar State, Venezuela, a paracoccidioidomycosis 
endemic zone. The patient was a 39 years old-man 
admitted to the hospital because of dyspnea, fever and 
wasting syndrome. The clinical presentation was an acute 
respiratory distress syndrome with severe hypoxemia 
and bilateral pulmonary infiltrates. In addition, oral 
moniliasis, low platelet, and elevated aminotransferases 
were found. Stools examination demonstrated hook- 
worm eggs and Giardia lamblia. An enzyme-linked 
immunosorbent assay and a Western blot assay for HIV- 
1 antibodies were positive, the CD4 cell count was 42 x 
mm3. The direct examination of the sputum (KOH) 
demon-strated multiple budding yeast cells: of F! 
brasiliensis; Gram stain was positive for Gram negative 
bacilli and high white cells count Gram negative bacilli; 
Ziehl-Neelsen and direct immunofluorescence for 
Pneumocystis carinii were negative. Sputum culture 
